- Home
- NERV vs OXBR Comparison
NERV vs OXBR Comparison
Compare NERV & OXBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NERV
- OXBR
- Stock Information
- Founded
- NERV 2007
- OXBR 2013
- Country
- NERV United States
- OXBR Cayman Islands
- Employees
- NERV N/A
- OXBR N/A
- Industry
- NERV Biotechnology: Pharmaceutical Preparations
- OXBR Property-Casualty Insurers
- Sector
- NERV Health Care
- OXBR Finance
- Exchange
- NERV Nasdaq
- OXBR Nasdaq
- Market Cap
- NERV 18.3M
- OXBR 15.8M
- IPO Year
- NERV 2014
- OXBR 2014
- Fundamental
- Price
- NERV $2.20
- OXBR $2.74
- Analyst Decision
- NERV Hold
- OXBR
- Analyst Count
- NERV 1
- OXBR 0
- Target Price
- NERV $5.00
- OXBR N/A
- AVG Volume (30 Days)
- NERV 25.3K
- OXBR 14.1K
- Earning Date
- NERV 11-05-2024
- OXBR 11-13-2024
- Dividend Yield
- NERV N/A
- OXBR N/A
- EPS Growth
- NERV N/A
- OXBR N/A
- EPS
- NERV N/A
- OXBR N/A
- Revenue
- NERV N/A
- OXBR N/A
- Revenue This Year
- NERV N/A
- OXBR N/A
- Revenue Next Year
- NERV N/A
- OXBR N/A
- P/E Ratio
- NERV N/A
- OXBR N/A
- Revenue Growth
- NERV N/A
- OXBR N/A
- 52 Week Low
- NERV $2.10
- OXBR $0.87
- 52 Week High
- NERV $13.49
- OXBR $3.72
- Technical
- Relative Strength Index (RSI)
- NERV 34.31
- OXBR 52.49
- Support Level
- NERV $2.26
- OXBR $2.41
- Resistance Level
- NERV $2.43
- OXBR $2.97
- Average True Range (ATR)
- NERV 0.16
- OXBR 0.22
- MACD
- NERV -0.01
- OXBR -0.01
- Stochastic Oscillator
- NERV 13.71
- OXBR 55.93
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
About OXBR Oxbridge Re Holdings Limited
Oxbridge Re Holdings Ltd is a specialty property and casualty reinsurer. It provides reinsurance solutions through its subsidiary. It focuses on underwriting fully collateralized reinsurance contracts primarily for property and casualty insurance companies in the Gulf Coast region of the United States, with an emphasis on Florida. Oxbridge specializes in underwriting medium frequency, high severity risks, where insufficient data exists to analyze effectively the risk/return profile of reinsurance contracts. The Company manages its business on the basis of one operating segment, Property and Casualty Reinsurance.